RxDoctor Payments DataLook up a doctor →

Kader Abdelerahman, MD

Neurology · Albuquerque, NMNPI 1003058157

Payments from drug & device makers

$606,569in general payments, 2019–2025

Across 1,634 payments — averaging $371.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$159K
  • AbbVie$151K
  • Neurocrine Biosciences, Inc.$108K
  • Biogen$46K
  • Sanofi$43K
  • Teva Pharmaceuticals USA, Inc.$35K
  • plus $63K from 54 others

What the payments were for

  • Consulting fees$83,12914%
  • Speaking & faculty fees$446,51874%
  • Travel & lodging$30,3845%
  • Food & beverage$44,6367%
  • Education$1,9030%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
EMD Serono, Inc.229$159,465
AbbVie(2 entities)319$151,101
Neurocrine Biosciences, Inc.155$108,387
Biogen124$46,493
Sanofi78$43,148
Teva Pharmaceuticals USA, Inc.84$35,035
Biohaven Pharmaceuticals, Inc.39$20,124
Amgen(2 entities)46$9,348
UCB, Inc.38$6,221
Argenx US, Inc.38$5,628
Biohaven Pharmaceutical Holding Company Ltd.18$5,554
Novartis79$1,983
Amneal Pharmaceuticals LLC18$1,764
AstraZeneca40$1,547
Acadia Pharmaceuticals Inc38$1,314
Pfizer29$1,009
Genentech USA, Inc.27$889
Lilly USA, LLC32$846
CSL Behring21$626
Lundbeck LLC15$568
SK Life Science, Inc.12$474
Eisai Inc.12$439
Neurelis, Inc.14$350
Jazz Pharmaceuticals Inc.8$328
Sunovion Pharmaceuticals Inc.19$257
Vertex4$252
Otsuka Pharmaceutical Development & Commercialization, Inc.2$249
Genentech, Inc.2$242
Acorda Therapeutics, Inc9$234
Johnson & Johnson(2 entities)4$231
TG Therapeutics, Inc.8$227
Banner Life Sciences, LLC9$221
Alnylam Pharmaceuticals Inc.4$171
Springworks Therapeutics, Inc.2$150
Ipsen Biopharmaceuticals, Inc5$147
Averitas Pharma Inc.2$137
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)1$135
Merz Pharmaceuticals, LLC6$117
Takeda Pharmaceuticals U.S.A., Inc.1$116
E.r. Squibb & Sons, L.L.C.1$111
W. L. Gore & Associates, Inc.1$100
Bristol Myers Squibb5$88
Upsher-smith Laboratories LLC1$71
Otsuka America Pharmaceutical, Inc.4$70
Tanabe Pharma America, Inc.4$63
Impel Pharmaceuticals Inc.3$52
Grifols USA, LLC2$48
Abbott3$47
Vertical Pharmaceuticals, LLC3$46
Sanofi-aventis U.S. LLC2$45
Catalyst Pharmaceuticals, Inc.2$44
GT Medical Technologies, Inc1$43
Impel Pharmaceuticals LLC1$40
GE HealthCare2$36
Kedrion Biopharma, Inc.2$36
Vanda Pharmaceuticals Inc.2$35
Kyowa Kirin, Inc.1$23
Portola Pharmaceuticals, LLC1$19
Cycle Pharmaceuticals Inc1$15
Intercept Pharmaceuticals, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$606,569 in reported general payments places this provider in the 95th percentile of 91 neurology providers in New Mexico.

See all neurology providers in New Mexico

Medicare billing

Part B allowed, 2024
$615,591
Medicare patients
444
Services billed
71,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant143$205,121
NuplazidPimavanserin Tartrate41$204,395
Aimovig AutoinjectorErenumab-Aooe128$125,110
Nurtec OdtRimegepant Sulfate88$124,043
Emgality PenGalcanezumab-Gnlm134$122,578
RytaryCarbidopa/Levodopa27$43,566
QuliptaAtogepant17$34,688
Ajovy AutoinjectorFremanezumab-Vfrm18$27,636
Ajovy SyringeFremanezumab-Vfrm32$27,154
Emgality SyringeGalcanezumab-Gnlm13$23,539
Dalfampridine ErDalfampridine20$22,578
Lacosamide119$22,527
OngentysOpicapone25$22,221
Rasagiline Mesylate84$14,082
Levetiracetam292$11,482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$151,101$239,808160 claims
Acadia Pharmaceuticals IncNuplazid$1,314$204,39541 claims
PfizerNurtec Odt$1,009$124,04388 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$1,764$45,11738 claims
Neurocrine Biosciences, Inc.Ongentys$108,387$22,22125 claims
Upsher-smith Laboratories LLCTopiramate$71$5,434209 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 91 neurology providers in New Mexico.

Other neurology in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →